Skip to content

Study · Randomized controlled trial · n = 21 · 2014

5 results

The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor.

Teng R, Mitchell PD, Butler K

Journal of clinical pharmacy and therapeutics21 Jan 2014Cited by 31 (Europe PMC)

PMID24444280 (opens in a new tab)DOI10.1111/jcpt.12130 (opens in a new tab)PepBankPUB-24444280
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers receiving ticagrelor, desmopressin slightly reduced median bleeding time to 7·50 versus 10·50 min at 2·5 h.

    In plain wordsIn healthy volunteers taking ticagrelor, added desmopressin slightly shortened bleeding time compared with ticagrelor alone.

    Peptide
    Desmopressin
    Outcome
    DecreaseBleeding time at 2·5 h
    Study

    n = 21

    Comparator
    ticagrelor alone
    Outcome group
    Bleeding · Cardiovascular
    Studied dose
    0·3 μg/kg · intravenousAs given in this study (human).

    Measurements

    Bleeding time
    7.5 min
    desmopressin plus ticagrelor
    Bleeding time range
    3 to 17 min
    desmopressin plus ticagrelor
    Bleeding time
    10.5 min
    ticagrelor alone
    Bleeding time range
    3 to 25 min
    ticagrelor alone

    Source sentences

    Summary
    Median [range] bleeding times were slightly reduced with ticagrelor plus desmopressin compared with ticagrelor alone (7·50 [3-17] vs. 10·50 [3-25] min at 2·5 h).
    2 context sentences
    Summary · context
    In a randomized, double-blind, 2-period crossover study, healthy volunteers received ticagrelor (270 mg loading dose; 180 mg bid) for 5 days.
    Summary · context
    On Day 5, desmopressin (0·3 μg/kg) or saline intravenous infusions were administered.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy volunteers receiving ticagrelor, median bleeding-time reductions were generally similar with added desmopressin and ticagrelor alone at all times.

    In plain wordsIn healthy volunteers taking ticagrelor, bleeding-time reductions were similar with added desmopressin and ticagrelor alone.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedBleeding time reduction from baseline
    Study

    n = 21

    Comparator
    ticagrelor alone
    Outcome group
    Bleeding · Cardiovascular
    Studied dose
    0·3 μg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Median reductions in bleeding time from baseline were generally similar between ticagrelor plus desmopressin compared with ticagrelor alone at all time points.
    2 context sentences
    Summary · context
    In a randomized, double-blind, 2-period crossover study, healthy volunteers received ticagrelor (270 mg loading dose; 180 mg bid) for 5 days.
    Summary · context
    On Day 5, desmopressin (0·3 μg/kg) or saline intravenous infusions were administered.
  3. 03HumanRandomized controlled trialActivity measurement

    In healthy volunteers receiving ticagrelor, added desmopressin had no impact on inhibition of platelet aggregation.

    In plain wordsIn healthy volunteers taking ticagrelor, added desmopressin did not change platelet aggregation inhibition compared with ticagrelor alone.

    Peptide
    Desmopressin
    Outcome
    No significant changeInhibition of platelet aggregation
    Study

    n = 21

    Comparator
    ticagrelor alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    0·3 μg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).
    2 context sentences
    Summary · context
    In a randomized, double-blind, 2-period crossover study, healthy volunteers received ticagrelor (270 mg loading dose; 180 mg bid) for 5 days.
    Summary · context
    On Day 5, desmopressin (0·3 μg/kg) or saline intravenous infusions were administered.
  4. 04HumanRandomized controlled trialActivity measurement

    In healthy volunteers receiving ticagrelor, desmopressin significantly increased platelet reactivity, with von Willebrand factor antigen AUEC of 4667 versus 2750%.h.

    In plain wordsIn healthy volunteers taking ticagrelor, added desmopressin increased platelet reactivity compared with ticagrelor alone.

    Peptide
    Desmopressin
    Outcome
    IncreasePlatelet reactivity and von Willebrand factor antigen AUEC
    Study

    n = 21

    Comparator
    ticagrelor alone
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    0·3 μg/kg · intravenousAs given in this study (human).

    Measurements

    von Willebrand Factor antigen GLS mean AUEC
    4667 %.h
    desmopressin plus ticagrelor
    von Willebrand Factor antigen GLS mean AUEC
    2750 %.h
    ticagrelor alone

    Source sentences

    Summary
    Co-administration of desmopressin had no impact on IPA, although platelet reactivity was significantly increased (von Willebrand Factor antigen: GLS mean AUEC was 4667%.h for ticagrelor plus desmopressin compared with 2750%.h for ticagrelor alone).
    2 context sentences
    Summary · context
    In a randomized, double-blind, 2-period crossover study, healthy volunteers received ticagrelor (270 mg loading dose; 180 mg bid) for 5 days.
    Summary · context
    On Day 5, desmopressin (0·3 μg/kg) or saline intravenous infusions were administered.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy volunteers receiving ticagrelor, desmopressin did not influence ticagrelor pharmacokinetics.

    In plain wordsIn healthy volunteers taking ticagrelor, added desmopressin did not change ticagrelor pharmacokinetics compared with ticagrelor alone.

    Peptide
    Desmopressin
    Outcome
    No significant changeTicagrelor pharmacokinetics
    Study

    n = 21

    Comparator
    ticagrelor alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    0·3 μg/kg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Desmopressin did not influence the pharmacokinetics of ticagrelor.
    2 context sentences
    Summary · context
    In a randomized, double-blind, 2-period crossover study, healthy volunteers received ticagrelor (270 mg loading dose; 180 mg bid) for 5 days.
    Summary · context
    On Day 5, desmopressin (0·3 μg/kg) or saline intravenous infusions were administered.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.